TEAEs in at least 10% of patients
| . | Once-weekly KRd56 (N = 223) . | Twice-weekly KRd27 (N = 231) . | ||
|---|---|---|---|---|
| Any-grade TEAEs . | Grade ≥3 TEAEs . | Any-grade TEAEs . | Grade ≥3 TEAEs . | |
| Overall, n (%) | 209 (93.7) | 141 (63.2) | 219 (94.8) | 144 (62.3) |
| Neutropenia | 65 (29.1) | 54 (24.2) | 74 (32.0) | 57 (24.7) |
| Anemia | 57 (25.6) | 26 (11.7) | 55 (23.8) | 20 (8.7) |
| Hypertension | 48 (21.5) | 21 (9.4) | 56 (24.2) | 23 (10.0) |
| Thrombocytopenia | 48 (21.5) | 27 (12.1) | 33 (14.3) | 24 (10.4) |
| Diarrhea | 42 (18.8) | 2 (0.9) | 44 (19.0) | 3 (1.3) |
| Upper respiratory tract infection | 32 (14.3) | 2 (0.9) | 33 (14.3) | 0 (0.0) |
| COVID-19 | 28 (12.6) | 7 (3.1) | 17 (7.4) | 4 (1.7) |
| Asthenia | 27 (12.1) | 5 (2.2) | 13 (5.6) | 3 (1.3) |
| Pyrexia | 25 (11.2) | 2 (0.9) | 28 (12.1) | 2 (0.9) |
| Fatigue | 24 (10.8) | 7 (3.1) | 29 (12.6) | 5 (2.2) |
| Constipation | 23 (10.3) | 2 (0.9) | 17 (7.4) | 0 (0.0) |
| . | Once-weekly KRd56 (N = 223) . | Twice-weekly KRd27 (N = 231) . | ||
|---|---|---|---|---|
| Any-grade TEAEs . | Grade ≥3 TEAEs . | Any-grade TEAEs . | Grade ≥3 TEAEs . | |
| Overall, n (%) | 209 (93.7) | 141 (63.2) | 219 (94.8) | 144 (62.3) |
| Neutropenia | 65 (29.1) | 54 (24.2) | 74 (32.0) | 57 (24.7) |
| Anemia | 57 (25.6) | 26 (11.7) | 55 (23.8) | 20 (8.7) |
| Hypertension | 48 (21.5) | 21 (9.4) | 56 (24.2) | 23 (10.0) |
| Thrombocytopenia | 48 (21.5) | 27 (12.1) | 33 (14.3) | 24 (10.4) |
| Diarrhea | 42 (18.8) | 2 (0.9) | 44 (19.0) | 3 (1.3) |
| Upper respiratory tract infection | 32 (14.3) | 2 (0.9) | 33 (14.3) | 0 (0.0) |
| COVID-19 | 28 (12.6) | 7 (3.1) | 17 (7.4) | 4 (1.7) |
| Asthenia | 27 (12.1) | 5 (2.2) | 13 (5.6) | 3 (1.3) |
| Pyrexia | 25 (11.2) | 2 (0.9) | 28 (12.1) | 2 (0.9) |
| Fatigue | 24 (10.8) | 7 (3.1) | 29 (12.6) | 5 (2.2) |
| Constipation | 23 (10.3) | 2 (0.9) | 17 (7.4) | 0 (0.0) |